newsfilter
← Latest News
PR Newswire·

Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

NKTR
  • Nektar Therapeutics closed an underwritten public offering of $373.8 million in common stock on April 23, 2026.
  • The company sold 4,529,891 total shares, comprising 4,062,500 primary shares plus 529,891 additional shares from the full exercise of the underwriters' option.
  • Shares were sold at a public offering price of $92.00 per share.
  • Gross proceeds of approximately $373.8 million were received before deducting underwriting discounts, commissions, and estimated offering expenses.
  • Jefferies, TD Cowen, & Piper Sandler acted as joint bookrunning managers, while Citigroup served as a bookrunner.
  • The offering was conducted under a shelf registration statement on Form S-3ASR (No. 333-291466) filed with the SEC on November 12, 2025.
  • Nektar Therapeutics is a clinical-stage biotechnology firm focused on immunology therapies for autoimmune & chronic inflammatory diseases.
  • The company's lead candidate, rezpegaldesleukin (NKTR-358), is currently in Phase 2b trials for atopic dermatitis, alopecia areata, & a Phase 2 trial for Type 1 diabetes mellitus.
  • Nektar's pipeline also includes preclinical bispecific programs (NKTR-0165, NKTR-0166) & a modified CSF protein (NKTR-422).
  • Nektar Therapeutics is headquartered in San Francisco, California.